Chemed Q1 2022: EPS up 7.9% on adjusted basis; VITAS revenue down 5.3%, Roto-Rooter up 9.4%

CHEMED CORP

2022-Q1 EPS reported $4.22 revenue$530,549,000

Consolidated revenue $531M (+0.6% YoY); GAAP diluted EPS $4.22 (+5.2%); adjusted diluted EPS $4.79 (+7.9%).
VITAS net patient revenue $299M (-5.3%), ADC 17,313 (-4.1%), admissions 16,530 (-8.9%).
Roto-Rooter revenue $231M (+9.4%); net income excl. discrete items $46.4M (+18.0%); adjusted EBITDA margin 28.5% (+160 bps).
Chemed repurchased 57,500 shares for $27.4M at avg. cost $475.71; remaining auth. ~$175M.
Management to provide updated 2022 earnings guidance in June 2022 earnings release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.